Advertisement
Advertisement
U.S. Markets close in 6 hrs 8 mins
Advertisement
Advertisement
Advertisement
Advertisement

Chembio Diagnostics, Inc. (CEMI)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.0939+0.0039 (+0.36%)
As of 09:52AM EST. Market open.
Advertisement
Sign in to post a message.
  • M
    Mav
    CHEMBIO DIAGNOSTICS SAYS FDA DECLINED TO REVIEW CO'S APPLICATION FOR EUA FOR DPP RESPIRATORY ANTIGEN PANEL

    https://www.cmlviz.com/stocks/CEMI/news/b/2021/12/28/chembio-diagnostics-says-fda-declined-to-review-co-s-application-for-eua-for-dpp-respiratory-antigen-panel
    Neutral
  • J
    Jordan
    can't believe I bought this at 14 back in 2020
  • M
    Mohan
    IMO- This company might go out of business with this pace of downfall
  • c
    canadian_baba
    This company is an old company, its not going anywhere, stock was .64 cents years ago. Came back up.
    Trust me its gonna go up, wait and watch.
  • V
    Vinny
    The US Government has announced that they are purchasing 500M testing kits.... from where and why doesn't this company have a sales team capitalizing on more testing needs for the Country, let alone Globally ? What are they doing ?
    Neutral
  • m
    michelle
    Up 8% hmmmm
  • B
    Boland
    @Tom What were you saying with your “Adios Shorts” post when I commented about their FDA clinicals?
  • E
    Elissa
    ⭐ This is a very Bullish Chart, traders! 💰💵📈

    https://stockreport.tips/Bullish-Charts
    Bullish
  • K
    Kimleng
    is the balance sheet shows 47 millions after debt?
  • i
    ith
    Why the sudden drop after hr
  • T
    Tom
    adios shorts!
  • b
    bluehorseshoe999
    Wow!!!!

    Down 5 straight days in a row from 1.80 to 1.09. Talk about a free fall!

    looks like FDA rejection to review EUA was catalysts to dump any shares left although FDA rejection has no impact since announcement about 3-4 weeks had no impact. Looks like market knew that no change in status quo with NDA app since PPS did not change much!

    New year around the corner and new hope rises!

    GLTA in stock casino!
  • s
    stocktracker000
    What a glorious day for shorts....

    Not worth shorting here....

    Rejection by FDA non event since PPS never popped with NDA submission.

    Purely EOY tax loss selling...

    Company's MC is 1x revenue. Too risky and PPS down from 1.80 to 1.1 in two days...

    Any decent news could pop this over 2...

    Good Luck to all and do your due diligence always...
    Neutral
  • M
    Md
    Item 8.01
    Other Matters.
     
    Request for Additional Data Related to CLIA Waiver Submission for DPP HIV-Syphilis Test System
     
    On December 1, 2021, we received notice from the U.S. Food and Drug Administration, or FDA, that the FDA would require additional data related to our Clinical Laboratory Improvement Amendment, or CLIA, waiver submission for the DPP HIV-Syphilis test system. We are in active discussions with the FDA in connection with the FDA’s review of our submission and we intend to seek to comply with the FDA’s request for additional data, but the process of seeking additional data will extend, for a currently undeterminable period, our process for seeking a CLIA waiver for the DPP HIV-Syphilis test system. We cannot assure you that we will be able to compile the additional data requested by the FDA in a timely manner or at all, and therefore we cannot assure you that a CLIA waiver will be granted with respect to the DPP HIV-Syphilis test system at any specific time in the future or at all.
     
    Scheduled Expiration of BARDA Agreement
     
    Our contract, which we refer to as the BARDA Agreement, dated December 2, 2020 with the Biomedical Advanced Research and Development Authority, or BARDA (part of the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response), expired in accordance with its terms on December 2, 2021. Under the BARDA Agreement, up to $12.7 million of awards were available from BARDA in order to assist us in (a) developing, and requesting an EUA from the FDA for, the DPP Respiratory Panel and (b) performing the clinical trials for and submitting the DPP SARS‑CoV‑2 Antigen test system to the FDA, for 510(k) clearance.
     
    As of September 30, 2021 we had earned a total of $9.6 million in grant income under the BARDA Agreement, and from October 1, 2021 through December 2, 2021 we earned an additional $2.9 million of grant income under the BARDA Agreement. As a result, we earned $12.5 million of the $12.7 million available under the BARDA Agreement, with the remaining $0.2 million having not been earned because it was contingent on our receiving an emergency use authorization for the DPP Respiratory Panel by December 2, 2021.
  • N
    NSX
    $6 and I'm sold! LOL Holding for the payout
    Bullish
  • H
    Henri
    bough this for 3$.. I only lost 2K thought. Waiting until it gets a bit higher and unloading,
  • S
    StraighttalkerDX
    Ruff day. Wonder if this stock is headed to same price of company former CEO is now at. Delisting notice not far off.
  • J
    JOHN
    I am looking forward to seeing 800% explosion in stock price.
    Bullish
  • J
    JOSH
    CEMI has a market cap of 33M, pennies...lmao. The company is only good for testing FECES. I am more than happy to give you my SAMPLE FECES. Please enjoy!
  • E
    Etrader
    $CEMI COVID-19 related
    Float 28.3 M
    Short Interest 11.03 ~ 14.66
    2 years high $15.89

    News: Chembio Diagnostics Receives SAHPRA Approval for DPP SARS-CoV-2 Antigen Test
    https://finance.yahoo.com/news/chembio-diagnostics-receives-sahpra-approval-130000218.html
    News: Chembio Files For FDA Emergency Use Nod For COVID-19 Antigen Test
Advertisement
Advertisement